glp-1 agonists and sglt2 inhibitors combination Receptor in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy | Drugs SGLT2 Inhibitors vs. GLP-1 Agonists
Description
Dose escalation should be gradual
Dual and multi-agonists, including agents targeting GLP-1/GIP and GLP-1/GCGR pathways, are emerging as next-generation therapies with enhanced metabolic benefits
Erratum in Lancet 2022, 399, 358
Neves JS, Borges-Canha M, Vasques-Nvoa F, et al
Beyond appetite control, it boosts calorie-burning by stimulating insulin release helping your body use stored fat for energy
doi: 10.1016/j.jacc.2024.02.020
